ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

13/05/2008 1:00pm

PR Newswire (US)


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more Sunesis Pharmaceuticals Charts.
SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will provide a corporate update at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference at 9:00 a.m. local time on Monday, May 19, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Interested parties may access a webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com/. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks. About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com/. DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: investors, Eric Bjerkholt, SVP, Corp. Development & Finance of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals, Inc. Web site: http://www.sunesis.com/

Copyright

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock